Clinical Research Directory
Browse clinical research sites, groups, and studies.
NMBA Reversal and Postoperative Urinary Retention
Sponsor: Beth Israel Deaconess Medical Center
Summary
In this single-center retrospective cohort study of adult patients who underwent surgery under general anesthesia at Beth Israel Deaconess Medical Center between September 2016 and January 2024, the association between the choice of neuromuscular blocking agent (NMBA) reversal strategy, comparing sugammadex with neostigmine (combined with a muscarinic antagonist), and postoperative urinary retention (POUR) will be evaluated. In secondary analyses, the effects of NMBA reversal strategy and POUR on costs of care and unplanned hospital visits will be analyzed.
Official title: The Choice of Neuromuscular Blockade Reversal Agent and Its Effects on Postoperative Urinary Retention: A Retrospective Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
70000
Start Date
2025-06-08
Completion Date
2026-06-01
Last Updated
2026-01-23
Healthy Volunteers
Yes
Conditions
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
The use of sugammadex or neostigmine (in co-administration with muscarinic antagonist) will be compared. The muscarinic antagonists that will be considered are atropine and glycopyrrolate.
Locations (1)
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States